- Home
- NTRB vs ELTX Comparison
NTRB vs ELTX Comparison
Compare NTRB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | ELTX |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 209.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NTRB | ELTX |
|---|---|---|
| Price | $3.70 | $10.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 12.4K | ★ 148.0K |
| Earning Date | 04-27-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.42 | $4.60 |
| 52 Week High | $11.68 | $14.93 |
Technical Indicators
Market Signals| Indicator | NTRB | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 49.37 |
| Support Level | $3.64 | $9.84 |
| Resistance Level | $4.50 | $11.12 |
| Average True Range (ATR) | 0.27 | 1.01 |
| MACD | -0.01 | -0.28 |
| Stochastic Oscillator | 39.01 | 18.86 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.